Physician profile
Brian Mcbreen
NPI 1316005952
$3,838.21
in general payments reported to CMS, 2019-2025
31 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $513 · 2021: $727 · 2022: $659 · 2023: $461 · 2024: $464 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.00 | 2019-2024 | |
| Pfizer INC. | $566.87 | 2019-2025 | |
| Amgen INC. | $350.35 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $263.65 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $216.24 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $200.91 | 2019-2025 | Capvaxive, Pneumovax 23, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company Ltd. | $161.63 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $159.21 | 2019-2022 | |
| Lilly USA, LLC | $154.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $113.48 | 2021-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.20 | 2019-2021 | |
| Amarin Pharma, INC. | $83.74 | 2020-2021 | |
| Exact Sciences Corporation | $65.39 | 2023-2024 | Cologuard Collection Kit |
| Seqirus USA INC | $63.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.01 | 2025 | Austedo Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $51.97 | 2019-2020 | |
| Radius Health, INC. | $51.08 | 2019 | |
| Sanofi Pasteur INC. | $42.34 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.73 | 2025 | |
| Aimmune Therapeutics, INC. | $27.58 | 2024 | |
| Becton, Dickinson and Company | $26.78 | 2025 | Bd Max System, Bd Max Instrument |
| Amneal Pharmaceuticals LLC | $26.48 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $25.83 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $24.88 | 2023 | Keveyis |
| Horizon Therapeutics Plc | $20.85 | 2021 | |
| Glaxosmithkline, LLC. | $14.54 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.33 | 2019 | |
| Eisai INC. | $13.72 | 2021 | |
| Allergan, INC. | $11.97 | 2020 | |
| Dynavax Technologies Corporation | $11.50 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcbreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.